November 29, 2024 Holiday Shopping Sets New Records With $6.1B Spent Online
November 25, 2024 Bitcoin Nears $100K: Crypto Revolution Reshapes Wall Street
November 18, 2024 Biden’s Missile Strategy: Escalation Or Path To Peace?
November 10, 2024 Wall Street Soars: Trump’s Victory Ignites Market Surge
Tesla Faces An Uphill Battle In 2025
Amazon: A Compelling Buying Opportunity
Xiaomi: Anatomy Of A Tesla Killer
Tesla’s Self-Driving Narrative Is Falling Apart
October 22, 2024 A Comprehensive Guide to RoadRunner Auto Transport Services
October 3, 2024 Mastering Trading Indicators: Your Essential Toolkit For Success
April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?
April 12, 2024 Improve Your Financial Status: A How-To Guide
Cortexyme (CRTX) Stock Forecast for 2024, 2025, 2026. Sell or Buy?
Updated: December 5, 2024 (07:22)
Sector: HealthcareThe share price of Cortexyme, Inc. (CRTX) now
Are you interested in Cortexyme, Inc. stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Cortexyme stock price in 2025, 2026, 2027. How much will one Cortexyme share be worth in 2025 - 2027?
When should I take profit in Cortexyme stock? When should I record a loss on Cortexyme stock? What are analysts' forecasts for Cortexyme stock? What is the future of Cortexyme stock? We forecast Cortexyme stock performance using neural networks based on historical data on Cortexyme stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account.
Cortexyme stock prediction results are shown below and presented in the form of graphs, tables and text information, divided into time intervals. (Next month, 2025, 2026, 2027, and ) The final quotes of the instrument at the close of the previous trading day are a signal to adjust the forecasts for Cortexyme shares. This happens once a day.
Historical and forecast chart of Cortexyme stock
The chart below shows the historical price of Cortexyme stock and a prediction chart for the next month.
For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast,
and Weighted Average Best Forecast. Detailed values for the Cortexyme stock price can be found in the table below.
Long-term forecasts by years.
Cortexyme, Inc., a clinical stage biopharmaceutical company, specializes in the development of therapeutics for the treatment of Alzheimer’s disease and other degenerative diseases. Its main drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule inhibitor of gingipain, which is in phase II/III clinical trials for use in patients with mild to moderate Alzheimer’s disease. Cortexyme Inc. is a partner of the Parkinson Study Group.
Cortexyme daily forecast for a month
| Date | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Dec 07 | 2.04 | 1.99 | 2.11 | 6.21 |
| Dec 08 | 2.06 | 2.01 | 2.11 | 5.23 |
| Dec 09 | 2.11 | 2.06 | 2.16 | 4.65 |
| Dec 10 | 2.13 | 2.05 | 2.21 | 7.84 |
| Dec 11 | 2.20 | 2.11 | 2.23 | 5.52 |
| Dec 12 | 2.28 | 2.22 | 2.33 | 4.87 |
| Dec 13 | 2.30 | 2.27 | 2.37 | 4.40 |
| Dec 14 | 2.29 | 2.23 | 2.34 | 5.15 |
| Dec 15 | 2.24 | 2.20 | 2.28 | 3.67 |
| Dec 16 | 2.21 | 2.16 | 2.26 | 4.43 |
| Dec 17 | 2.17 | 2.10 | 2.25 | 7.42 |
| Dec 18 | 2.18 | 2.10 | 2.21 | 5.28 |
| Dec 19 | 2.15 | 2.12 | 2.17 | 2.38 |
| Dec 20 | 2.10 | 2.08 | 2.12 | 2.17 |
| Dec 21 | 2.11 | 2.03 | 2.19 | 7.91 |
| Dec 22 | 2.15 | 2.12 | 2.22 | 4.67 |
| Dec 23 | 2.15 | 2.12 | 2.18 | 2.89 |
| Dec 24 | 2.13 | 2.05 | 2.15 | 5.19 |
| Dec 25 | 2.08 | 2.03 | 2.15 | 6.01 |
| Dec 26 | 2.10 | 2.05 | 2.13 | 4.22 |
| Dec 27 | 2.06 | 2.03 | 2.14 | 4.95 |
| Dec 28 | 2.05 | 1.98 | 2.09 | 5.71 |
| Dec 29 | 2.01 | 1.95 | 2.04 | 4.27 |
| Dec 30 | 2.09 | 2.05 | 2.17 | 5.82 |
| Dec 31 | 2.08 | 2.06 | 2.15 | 4.35 |
| Jan 01 | 2.10 | 2.06 | 2.14 | 3.89 |
| Jan 02 | 2.04 | 2.00 | 2.06 | 2.96 |
| Jan 03 | 2.06 | 2.04 | 2.14 | 5.01 |
| Jan 04 | 2.02 | 2.00 | 2.07 | 3.24 |
| Jan 05 | 1.93 | 1.85 | 1.99 | 7.29 |
Cortexyme Daily Price Targets
Cortexyme Stock Forecast 12-07-2024.
Forecast target price for 12-07-2024: $2.04.
Positive dynamics for Cortexyme shares will prevail with possible volatility of 5.851%.
Pessimistic target level: 1.99
Optimistic target level: 2.11
Cortexyme Stock Forecast 12-08-2024.
Forecast target price for 12-08-2024: $2.06.
Positive dynamics for Cortexyme shares will prevail with possible volatility of 4.973%.
Pessimistic target level: 2.01
Optimistic target level: 2.11
Cortexyme Stock Forecast 12-09-2024.
Forecast target price for 12-09-2024: $2.11.
Positive dynamics for Cortexyme shares will prevail with possible volatility of 4.447%.
Pessimistic target level: 2.06
Optimistic target level: 2.16
Cortexyme Stock Forecast 12-10-2024.
Forecast target price for 12-10-2024: $2.13.
Positive dynamics for Cortexyme shares will prevail with possible volatility of 7.267%.
Pessimistic target level: 2.05
Optimistic target level: 2.21
Cortexyme Stock Forecast 12-11-2024.
Forecast target price for 12-11-2024: $2.20.
Positive dynamics for Cortexyme shares will prevail with possible volatility of 5.229%.
Pessimistic target level: 2.11
Optimistic target level: 2.23
Cortexyme Stock Forecast 12-12-2024.
Forecast target price for 12-12-2024: $2.28.
Positive dynamics for Cortexyme shares will prevail with possible volatility of 4.645%.
Pessimistic target level: 2.22
Optimistic target level: 2.33
CRTX (CRTX) Monthly Stock Prediction for 2025
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Jan. | 2.08 | 1.97 | 2.16 | 9.04 |
| Feb. | 2.15 | 2.05 | 2.27 | 9.64 |
| Mar. | 2.10 | 1.94 | 2.23 | 12.83 |
| Apr. | 2.28 | 1.99 | 2.45 | 18.96 |
| May. | 2.37 | 2.25 | 2.72 | 17.25 |
| Jun. | 2.84 | 2.60 | 3.01 | 13.58 |
| Jul. | 3.20 | 2.88 | 3.53 | 18.33 |
| Aug. | 3.44 | 3.26 | 3.89 | 16.11 |
| Sep. | 3.57 | 3.10 | 3.82 | 18.88 |
| Oct. | 3.51 | 2.95 | 3.72 | 20.75 |
| Nov. | 3.55 | 3.38 | 4.09 | 17.36 |
| Dec. | 3.50 | 3.12 | 3.94 | 20.82 |
Cortexyme forecast for this year
Cortexyme Stock Prediction for Jan 2025
An uptrend is forecast for this month with an optimal target price of $2.07792. Pessimistic: $1.97. Optimistic: $2.16
Cortexyme Stock Prediction for Feb 2025
An uptrend is forecast for this month with an optimal target price of $2.14857. Pessimistic: $2.05. Optimistic: $2.27
Cortexyme Stock Prediction for Mar 2025
An downtrend is forecast for this month with an optimal target price of $2.1013. Pessimistic: $1.94. Optimistic: $2.23
Cortexyme Stock Prediction for Apr 2025
An uptrend is forecast for this month with an optimal target price of $2.27781. Pessimistic: $1.99. Optimistic: $2.45
Cortexyme Stock Prediction for May 2025
An uptrend is forecast for this month with an optimal target price of $2.36892. Pessimistic: $2.25. Optimistic: $2.72
Cortexyme Stock Prediction for Jun 2025
An uptrend is forecast for this month with an optimal target price of $2.83797. Pessimistic: $2.60. Optimistic: $3.01
Cortexyme Stock Prediction for Jul 2025
An uptrend is forecast for this month with an optimal target price of $3.20123. Pessimistic: $2.88. Optimistic: $3.53
Cortexyme Stock Prediction for Aug 2025
An uptrend is forecast for this month with an optimal target price of $3.43812. Pessimistic: $3.26. Optimistic: $3.89
Cortexyme Stock Prediction for Sep 2025
An uptrend is forecast for this month with an optimal target price of $3.56877. Pessimistic: $3.10. Optimistic: $3.82
Cortexyme Stock Prediction for Oct 2025
An downtrend is forecast for this month with an optimal target price of $3.51167. Pessimistic: $2.95. Optimistic: $3.72
Cortexyme Stock Prediction for Nov 2025
An uptrend is forecast for this month with an optimal target price of $3.54679. Pessimistic: $3.38. Optimistic: $4.09
Cortexyme Stock Prediction for Dec 2025
An downtrend is forecast for this month with an optimal target price of $3.50422. Pessimistic: $3.12. Optimistic: $3.94
Cortexyme (CRTX) Monthly Stock Prediction for 2026
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Jan | 3.81 | 3.57 | 4.25 | 15.95 |
| Feb | 3.82 | 3.22 | 4.36 | 26.14 |
| Mar | 4.42 | 3.79 | 4.86 | 22.04 |
| Apr | 4.72 | 4.41 | 5.41 | 18.32 |
| May | 5.62 | 5.21 | 6.11 | 14.73 |
| Jun | 6.41 | 5.74 | 7.13 | 19.42 |
| Jul | 6.78 | 6.43 | 7.35 | 12.55 |
| Aug | 5.47 | 4.84 | 6.31 | 23.22 |
| Sep | 5.22 | 4.86 | 5.48 | 11.26 |
| Oct | 5.08 | 4.40 | 5.81 | 24.30 |
| Nov | 5.00 | 4.30 | 5.65 | 23.89 |
| Dec | 5.25 | 4.94 | 5.63 | 12.13 |
Cortexyme (CRTX) Monthly Stock Prediction for 2027
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Jan | 4.85 | 4.37 | 5.15 | 15.07 |
| Feb | 5.41 | 4.78 | 5.70 | 16.13 |
| Mar | 5.71 | 5.19 | 5.99 | 13.36 |
| Apr | 6.14 | 5.69 | 6.85 | 16.85 |
| May | 6.71 | 5.96 | 7.65 | 22.11 |
| Jun | 5.73 | 5.06 | 6.42 | 21.25 |
| Jul | 4.69 | 4.41 | 5.07 | 13.12 |
| Aug | 5.03 | 4.37 | 5.30 | 17.46 |
| Sep | 4.83 | 4.22 | 5.28 | 20.11 |
| Oct | 4.37 | 3.72 | 4.90 | 24.11 |
| Nov | 5.18 | 4.46 | 5.77 | 22.62 |
| Dec | 5.16 | 4.83 | 5.88 | 17.89 |
Cortexyme information and performance
N/A
Market capitalization of the Cortexyme, Inc. is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of CRTX shares in the company outstanding by the market price of one share.
EBITDA of Cortexyme is earnings before interest, income tax and depreciation of assets.
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
Price/earnings to growth
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS shows how much of the net profit is accounted for by the common share.
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward P/E uses projections of future earnings instead of final numbers.
Enterprise Value (EV) /Revenue
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Number of issued ordinary shares
Number of freely tradable shares
Shares Short Prior Month - the number of shares in short positions in the last month.
